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Abstract
Background: Depot medroxyprogesterone acetate (DMPA) contraceptive use is associated with an increased risk
for Chlamydia infection. However, prior studies inadequately account for potential differences in sexual behavior
between users of DMPA and users of other contraceptive methods. In this study we compare sexual risk-taking
behavior in women using DMPA to women using oral contraceptive pills (OCP) to assess risk of Chlamydia
trachomatis infection.
Methods: In this cross-sectional study of 630 reproductive-aged women seeking routine gynecologic care
(449 OCP and 181 DMPA users) sexual risk-taking was evaluated by use of the Safe Sex Behavior Questionnaire, a
validated measure of sexual behaviors and attitudes. All women were screened for Chlamydia. Logistic regression
estimated the association of contraceptive choice, sexual behaviors, and Chlamydia infection.
Results: Oral contraceptive pill users differed from DMPA users in age, race, marital status, education level, and
pregnancy history (p-values all <0.05). Oral contraceptive pill users had used their method of contraception for
longer average duration (p < 0.01) and reported greater frequency of condom use (p < 0.01). Eleven (2.5%) OCP
and 2 (1.1%) DMPA users had Chlamydia (p = NS).
Conclusions: Oral contraceptive pill and DMPA users differed with respect to both demographic factors and
frequency of condom use. Odds of current Chlamydia infection did not differ between OCP and DMPA users
when controlling for sexual risk-taking or demographic factors, though due to low Chlamydia rates in our
population, this study was underpowered to detect this difference.
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Background
The injectable hormonal contraceptive depot medroxy-
progesterone acetate (DMPA) is currently used by over
41 million women worldwide [1]. The ease of adminis-
tration, high efficacy, lack of estrogen and duration of
action make DMPA an attractive contraceptive for many
women around the world.
Chlamydia trachomatis is the most commonly reported
sexually transmitted infection (STI), and its incidence
continues to rise by 3.3–4.9% per year for US women [2].
Three prospective human studies suggest that use of
DMPA for contraception increases a woman’s risk for
Chlamydia infection, with hazard ratios (HR) for
Chlamydia infection reported as high as 3.6 when com-
pared to oral contraceptive pill users [3, 4] or contracep-
tive non-users [3, 5]. The authors of these studies have
primarily posited physiologic changes induced by exogen-
ous hormone administration, such as changes in the
immune system or vaginal and cervical epithelia, as the
cause of higher Chlamydia acquisition among users of
DMPA [3, 5]. However, follow up analysis and investiga-
tion of functional change of cervical ectopy [3, 5, 6],
vaginal pH [5], or cervicovaginal flora [7] have not demon-
strated a difference in DMPA users as compared to non-
hormonal contraception users.
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These previous studies that have focused on a physio-
logic mechanism to explain the association of DMPA
use and Chlamydia acquisition have inadequately con-
trolled for sexual behaviors that may put DMPA users at
risk for sexually transmitted infections [3–5]. Depot
medroxyprogesterone acetate users may differ from
users of other methods or from non-contraceptors be-
cause DMPA is a simple-to-use method well-suited to
women with busy schedules, chaotic lives, or intermit-
tent access to health care. These life characteristics may
be associated with higher-risk sexual behavior.
We therefore sought to investigate whether the appar-
ent association between use of DMPA and heightened
risk for Chlamydia acquisition could be an artifact of
uncontrolled confounding variables, particularly sexual
risk-taking. We chose to compare DMPA users to oral
contraceptive pill (OCP) users because both methods are
reversible hormonal methods that afford excellent
protection against pregnancy, no protection against
Chlamydia acquisition, and both are frequently used by
young women, a population at risk for Chlamydia
infection [8].
Methods
Consecutive women presenting for routine gynecologic
care at a high-volume, urban reproductive health clinic
were recruited to participate if they met the following
criteria: were 18–49 years old, had initiated use of either
DMPA or OCPs at least 1 week prior to the study visit,
and could speak and read either English or Spanish.
Women who were pregnant, had a prior total hyster-
ectomy, or a recent cervical procedure (such as a
colposcopically directed biopsy or cone), a potential
non-behavioral risk factor for cervical infection, were
ineligible. Participants may or may not have been
presenting for STI testing as part of their care; the
reason for the visit of all subjects was recorded. We
presumed a Chlamydia prevalence of 13% in DMPA
users versus 5% in OCP users based on existing na-
tional data from similar clinical settings [9], estimated
that we would be able to recruit at a 1:2 ratio into the
DMPA and OCP arms, respectively, and calculated that
we would need at least 675 subjects (225 in the DMPA
arm and 450 in the OCP arm) to detect a difference of 8%
in the prevalence of Chlamydia between DMPA and OCP
users with 90% power and two-sided alpha of 0.05% and
assuming a 10% study noncompliance rate. Subject con-
sent to participate was given verbally in order to maintain
complete anonymity given the sensitive nature of the be-
havioral data collected. The study received approval from
Partners Healthcare Human Research Committee IRB.
Upon enrollment, participants completed a 47-item paper,
self-administered survey, half of which collected informa-
tion regarding sociodemographics, obstetric, gynecologic
and STI history, STI knowledge, contraceptive method
history, and condom use. The second half of the survey
contained 24 questions from the Safe Sex Behavior Ques-
tionnaire (SSBQ), a validated measure of sexual behaviors
and attitudes designed to assess level of sexual risk-taking
[10]. The responses for this 24-item survey are all given on
a 4-point Likert scale, resulting in a summed risk-taking
score ranging from 24 to 96, with a higher score suggestive
of safer, lower risk-taking sexual behavior.
Participants provided a urine specimen to detect
Chlamydia trachomatis through nucleic acid amplifica-
tion, with results reported as binary positive or negative
[11]. These urine specimens, labeled anonymously by
study number only, were collected, stored, transported
and analyzed in the exact manner as all Chlamydia tests
performed in this clinic outside of the study during this
same time period [12]. At enrollment, all participants
were given a copy of their personal study number and a
phone number to call a study nurse for Chlamydia re-
sults. This was the only way subjects could access their
anonymous study results; those patients who did not call
study nurse with their study number did not receive
their culture results. Subjects who called and were found
to be positive were required to identify themselves over
the phone in order to be prescribed antibiotic therapy.
Subjects who desired or had clinical indications for rou-
tine STI testing and follow-up by clinical staff had been
offered additional testing under normal procedures at
the clinic on the day of their visit before study enroll-
ment. Therefore, some subjects had two Chlamydia cul-
tures sent, one from their clinic visit and one from the
study protocol. The IRB approved these Chlamydia
reporting procedures.
We compared numerical variables, including the sum-
mated SSBQ score, between the two birth control
groups using either t-tests or Wilcoxon Rank-Sum tests.
No pattern in missing SSBQ responses was apparent and
because omissions appeared to be randomly distributed
in the sample, median substitution method was used for
the analysis where applicable.
We compared categorical variables using Chi-square
or Fisher’s exact tests. Chlamydia infection rates were
reported with exact 95% confidence intervals. We
performed logistic regression to assess the relationship
between contraceptive method and Chlamydia infection
adjusting for potential confounding variables. P-values
and odds ratios with 95% confidence intervals are
reported. All analyses were performed with SAS v9.2
statistical software (SAS Institute, Cary, NC).
Results
Over the course of 12 months of May 2007 to May 2008
we approached 1,869 patients. Nine hundred thirty-five
were not current OCP or DMPA users and thus, did not
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meet eligibility. Six hundred thirty-one of 934 eligible
patients elected to participate, for a participation rate of
67.6%. The study was closed before full recruitment of the
DMPA exposure arm was completed (225 intended partic-
ipants) because the lower than expected Chlamydia rates
would require an unfeasibly large sample size to detect a
difference between groups. One OCP participant who did
not complete half of the survey data pertaining to sexual
risk-taking was excluded from analysis; the final analytic
sample includes 630 study participants, 449 OCP and 181
DMPA users. Overall response rate for each question was
very high with fewer than 3% of responses missing for all
scale items except one, “I avoid sexual intercourse when I
have sores or irritation in my genital area” (9.8% missing).
Demographic characteristics of OCP and DMPA users
are summarized in Table 1; the two exposure arms dif-
fered in all demographic measures. The overall mean
sexual risk-taking score as assessed by the SSBQ was not
significantly different between subjects using OCPs
(55.7 ± 6.9) versus DMPA (54.5 ± 7.8) (p = 0.09). Table 2
summarizes associations between contraceptive method
and selected items on the SSBQ. Oral contraceptive
users reported longer duration of current contraceptive
method use (p < 0.01) and greater condom use (p < 0.01).
Age of first sex was found to be earlier in DMPA users
(p < 0.01) and fewer DMPA users co-habited with their
current partners compared to OCP users (p < 0.01). Oral
contraceptive users more frequently stated that their
primary reason for visiting the clinic at the time of study
enrollment was to get tested for STIs due to symptoms
or suspected exposure (p < 0.01). Subjects who presented
for STI testing in either group were more likely to test
positive for Chlamydia (p < 0.01). However, the relation-
ship between contraceptive method and Chlamydia
infection remained non-significant after adjusting for the
reason for the visit.
Eleven OCP users (2.5%, 95% CI: 1.4–4.3%) and two
DMPA users (1.1%, 95% CI: 0.3–3.9%) tested positive for
Chlamydia (p = NS). The mean sexual risk-taking score
was not statistically different between subjects with
(53.9 ± 6.9) and without (55.4 ± 7.2) Chlamydia infection.
The lack of significant difference in the odds of
Chlamydia infection according to contraceptive method
persisted after adjusting for sexual risk-taking scores.
Table 1 Baseline subject characteristics by birth control method used (n = 630)
Characteristic OCP Users (n = 449) DMPA Users (n = 181) P value
Age in years, mean [range] 23 [21, 26] 24 [22, 27] 0.04
Race <0.01
White/European American 347 (77.3) 103 (56.9)
Black/African American 19 (4.2) 38 (21.0)
Latina 23 (5.1) 24 (13.3)
Other 60 (13.4) 16 (8.8)
Marital Status <0.01
Single 201 (44.8) 59 (32.6)
Married 15 (3.3) 15 (8.3)
Divorced 2 (0.5) 3 (1.7)
In a relationship 231 (51.5) 104 (57.5)
Education <0.01
High school or less 24 (5.4) 29 (16.0)
Some college 133 (29.6) 72 (39.8)
College graduate 206 (46.0) 54 (29.8)
Graduate or professional school 86 (19.2) 26 (14.4)
Income (personal, annual) <0.01
$9,999 or less 187 (41.8) 50 (27.8)
$10,000–34,999 162 (36.2) 80 (44.4)
$35,000 or more 98 (21.9) 50 (27.8)
Number of Prior Pregnancies
Mean [range]
0 [0, 0] 1 [0, 2] <0.01
Any prior Pregnancy 89 (19.9) 92 (50.8) <0.01
Categorical variables are presented with frequency counts (%). Numerical variables are presented with mean [range] as noted
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Lastly, there was no significant association between the
frequency of Chlamydia infection and contraceptive
method after adjusting for race and marital status.
Discussion
We sought to assess whether women who chose a short-
term, high-maintenance contraceptive method, the daily
OCP, differ in risk-taking behavior from women who
chose the long-acting, low-maintenance DMPA injection.
We found that DMPA and OCP users did differ in both
sexual risk-taking behaviors and in demographics, such as
relationship status, that may influence Chlamdyia
acquisition risk. However, due to unexpectedly low
Chlamydia infection rates within our population, this
study was underpowered to detect a difference in in-
fection prevalence.
The hypothesized physiological pathway for an associ-
ation between DMPA and Chlamydia is challenged by
other investigations that have found a possible protective
effect [13] or no effect [14, 15] of hormonal contracep-
tion use on risk of Chlamydia acquisition. Furthermore,
while a recent meta-analysis demonstrated an increased
acquisition of another sexually transmitted infection,
HIV, among DMPA users, the evidence suggests that
there is a behavioral component to this risk. The risk of
HIV was higher in all women who use DMPA (pooled
Table 2 Selected Safe Sex Behavioral Questionnaire responses by birth control method used (n = 630)
Question OCP Users (n = 449) DMPA Users (n = 181) P value
Condom use: <0.01
Never or 0% of the time 43 (9.6) 30 (16.7)
Vary rarely-25% of the time 129 (28.7) 65 (36.3)
25-75% of the time 140 (31.2) 40 (22.4)
Almost always -100% of the time 137 (30.5) 44 (24.6)
When did you start using current BC method? <0.01
Less than 12 months ago 110 (24.5) 77 (42.8)
12–23 months ago 92 (20.5) 31 (17.2)
24–48 months ago 96 (21.4) 39 (21.7)
More than 48 months ago 151 (33.6) 33 (18.3)
Sexually Transmitted Infection 0.88
Have you ever been diagnosed with a sexually transmitted infection?
Yes 75 (16.7) 31 (17.2)
No 374 (83.3) 150 (82.8)
How old were you when you had sex very first time? 17.5 ± 2.2 16.9 ± 2.3 <0.01
How many men have you had sex with? 6 [3, 11] 6 [3, 10] 0.82
Are you monogamous? 0.28
Yes 365 (81.5) 157 (86.7)
No 37 (8.2) 11 (6.1)
Not sexually active 46 (10.3) 13 (7.2)
Are condoms effective? 0.72
Not at all 6 (1.4) 4 (2.2)
Somewhat 151 (33.6) 61 (33.9)
Very 292 (65.0) 115 (63.9)
Have you ever been treated for a sexually transmitted infection? 0.69
Yes 5 (1.1) 3 (1.7)
No 444 (98.9) 178 (98.3)
Are you currently living with a sexual partner? <0.01
Yes 133 (30.0) 80 (44.2)
No 316 (70.4) 101 (55.8)
Reason for appointment <0.01
Vaginal itching/STI 136 (30.3) 10 (5.5)
Categorical variables are presented with frequency counts (%). Numerical variables are presented with mean ± SD or median [Q1, Q3]
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HR 1.40, 95% CI 1.16–1.69) compared with use of non-
hormonal or no method. However, this effect was atten-
uated when analysis was restricted to the eight studies
recruiting from the general population (pooled HR 1.31,
95% CI 1.10–1.57), excluding studies from populations
with high-risk sexual lifestyles such as commercial sex-
workers [16]. Estimates for HIV risk with DMPA use
were higher from studies of women with high-risk life-
styles (HR 1.73, 95% CI 1.28–2.34 [17] and HR 3.93
1.37–11.2 [18]).
Our low Chlamydia rate may in part reflect bias intro-
duced by self-selection into the study population. While
we took measures to reassure patients of the anonymous
nature of data collection, given the sensitive nature of
the sexual behavior questions that were queried and the
resulting patient-directed Chlamydia result reporting, it
is possible that women who considered themselves to be
at higher risk for infection chose not to participate, bias-
ing our sample towards a non-infected population. Since
our study inclusion criteria excluded patients initiating a
new contraceptive method, it is also possible that we
recruited women who had recently started their contra-
ceptive method at the clinic and who had been previ-
ously screened, diagnosed, and treated for Chlamydia as
part of a relatively recent contraception initiation visit.
The reliability and validity of patient-reported sexual
history data has been studied with conflicting results
[19, 20]. Our use of a validated survey instrument and
anonymous study design was intended to minimize
reporting bias and promote accuracy of behavioral self-
reports. However, only a randomized controlled trial of
contraceptive methods would be sufficient to resolve all
potential behavioral confounders in exploring the
relationship between hormonal contraception and STI
acquisition, including reporting bias that is potentially
differential with respect to predictors of interest. Several
studies have randomized subjects to hormonal versus
non-hormonal contraception and found discontinuation
and pregnancy rates similar to the general population
using these contraceptive methods [21–23], discounting
concerns that randomization to contraceptive method is
unethical. Furthermore, Hubacher and colleagues [24]
conducted a cross-sectional survey to assess the feasibil-
ity of randomizing women to an intrauterine device or
DMPA in order to assess STI risk in DMPA users, and
found that 70% of respondents stated they would accept
randomization into one of these treatment arms.
Conclusion
Depot medroxyprogesterone acetate is an important
contraceptive method for many women around the world.
Our findings suggest that women who choose DMPA may
have behavioral risk factors that increase their risk for
STI’s, however, composite sexual risk-taking scores did
not differ between DMPA and OCP users. This study was
underpowered to detect a difference in Chlamydia rates
between users of these two contraceptive methods. Inter-
ventions should be directed towards improved safe-sex be-
havior amongst DMPA users. Experts at the World Health
Organization have recently reviewed the data on DMPA
and STI risk and agree that prior work suggesting an asso-
ciation between progesterone-only injectable contracep-
tion and STI acquisition have important methodological
limitations that hinder interpretation, that DMPA is still a
good method of contraception for women, and that
instead of directing patients away from this method in
order to decrease STI risk, clinicians should promote STI
preventative measures, such as male and female condoms
among DMPA users [25].
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